Jordi Codony‐Servat

3.4k total citations · 1 hit paper
56 papers, 2.5k citations indexed

About

Jordi Codony‐Servat is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jordi Codony‐Servat has authored 56 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 30 papers in Pulmonary and Respiratory Medicine and 25 papers in Molecular Biology. Recurrent topics in Jordi Codony‐Servat's work include Lung Cancer Treatments and Mutations (21 papers), Cytokine Signaling Pathways and Interactions (7 papers) and Lung Cancer Research Studies (7 papers). Jordi Codony‐Servat is often cited by papers focused on Lung Cancer Treatments and Mutations (21 papers), Cytokine Signaling Pathways and Interactions (7 papers) and Lung Cancer Research Studies (7 papers). Jordi Codony‐Servat collaborates with scholars based in Spain, United States and Italy. Jordi Codony‐Servat's co-authors include Joan Albanell, José Baselga, Joaquı́n Arribas, Federico Rojo, Rafael Rosell, Begoña Mellado, Juan Carlos López-Talavera, Niki Karachaliou, Pere Gascón and Pedro L. Fernández and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Jordi Codony‐Servat

54 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

2001 614 citations Jordi Codony‐Servat, Joan Albanell et al. PubMed profile →

Peers

Jordi Codony‐Servat

ONCOL

PRM

RNMI

Cammie Rinehart United States

Giorgio Valabrega Italy

Mari Iida United States

Joan T. Garrett United States

Anne T. Truesdale United States

Jennifer R. Diamond United States

Suleiman Massarweh United States

Patricia M. McGowan Ireland

Vincenzo Damiano Italy

Michael S. Toss United Kingdom

Cammie Rinehart United States

Jordi Codony‐Servat

1.7k ×1.1

ONCOL

1.7k ×1.4

567 ×0.9

PRM

719 ×1.2

RNMI

327 ×0.6

Citations per year, relative to Jordi Codony‐Servat Jordi Codony‐Servat (= 1×) peers Cammie Rinehart

Countries citing papers authored by Jordi Codony‐Servat

Since Specialization

Citations

This map shows the geographic impact of Jordi Codony‐Servat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jordi Codony‐Servat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jordi Codony‐Servat more than expected).

Fields of papers citing papers by Jordi Codony‐Servat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jordi Codony‐Servat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jordi Codony‐Servat. The network helps show where Jordi Codony‐Servat may publish in the future.

Co-authorship network of co-authors of Jordi Codony‐Servat

This figure shows the co-authorship network connecting the top 25 collaborators of Jordi Codony‐Servat. A scholar is included among the top collaborators of Jordi Codony‐Servat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jordi Codony‐Servat. Jordi Codony‐Servat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bertrán-Alamillo, Jordi, Núria Jordana‐Ariza, Ana Giménez‐Capitán, et al.. (2024). Vaccine antibodies against a synthetic epidermal growth factor variant enhance the antitumor effects of inhibitors targeting the MAPK/ERK and PI3K/Akt pathways. Translational Oncology. 40. 101878–101878.

Rosell, R., Jordi Codony‐Servat, Jessica González, et al.. (2023). KRAS G12C-mutant driven non-small cell lung cancer (NSCLC). Critical Reviews in Oncology/Hematology. 195. 104228–104228. 14 indexed citations

Rosell, Rafael, Anisha Jain, Jordi Codony‐Servat, et al.. (2023). Biological insights in non-small cell lung cancer. Cancer Biology and Medicine. 20(7). 1–19. 21 indexed citations

Rosell, Rafael, Andrés F. Cardona, Óscar Arrieta, et al.. (2021). Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities. British Journal of Cancer. 125(12). 1602–1611. 31 indexed citations

Rodríguez‐Abreu, Delvys, Manuel Cobo, Santiago Viteri, et al.. (2021). The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC. Lung Cancer. 164. 8–13. 3 indexed citations

Attili, Ilaria, Laura Bonanno, Niki Karachaliou, et al.. (2020). SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer. Translational Lung Cancer Research. 9(5). 1810–1821. 11 indexed citations

Bracht, Jillian Wilhelmina Paulina, Niki Karachaliou, Jordi Berenguer, et al.. (2019). PIM-1 inhibition with AZD1208 to prevent osimertinib-induced resistance in EGFR-mutation positive non-small cell lung cancer. Journal of Cancer Metastasis and Treatment. 2019. 12 indexed citations

Bertrán-Alamillo, Jordi, Valérie Cattan, Marie Schoumacher, et al.. (2019). AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy. Nature Communications. 10(1). 1812–1812. 88 indexed citations

Bracht, Jillian Wilhelmina Paulina, Niki Karachaliou, Jordi Berenguer, et al.. (2019). Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC). International Journal of Biological Sciences. 15(12). 2607–2614. 28 indexed citations

10.

Codony‐Servat, Jordi, Miguel Ángel Molina‐Vila, Jordi Bertrán-Alamillo, et al.. (2018). Anti–Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells. Journal of Thoracic Oncology. 13(9). 1324–1337. 29 indexed citations

11.

Karachaliou, Niki, Andrés F. Cardona, Jillian Wilhelmina Paulina Bracht, et al.. (2018). Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC). EBioMedicine. 39. 207–214. 35 indexed citations

12.

Jacobsen, Kirstine, Jordi Bertrán-Alamillo, Miguel Ángel Molina‐Vila, et al.. (2017). Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nature Communications. 8(1). 410–410. 118 indexed citations

13.

Marín‐Aguilera, Mercedes, Jordi Codony‐Servat, Òscar Reig, et al.. (2014). Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer. Molecular Cancer Therapeutics. 13(5). 1270–1284. 123 indexed citations

14.

Codony‐Servat, Jordi, Xabier García‐Albéniz, Carles Pericay, et al.. (2013). Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer. Medical Oncology. 30(1). 428–428. 4 indexed citations

15.

Marín‐Aguilera, Mercedes, Jordi Codony‐Servat, Susana G. Kalko, et al.. (2011). Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics. 11(2). 329–339. 86 indexed citations

16.

Carrera, Gemma, Xabier García‐Albéniz, Juan Ramón Ayuso, et al.. (2011). Design and endpoints of clinical and translational trials in advanced colorectal cancer. Reviews on Recent Clinical Trials. 6(2). 1 indexed citations

17.

Codony‐Servat, Jordi, Marta Bosch, Cristina Oliva, et al.. (2006). Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Molecular Cancer Therapeutics. 5(3). 665–675. 88 indexed citations

18.

Domingo‐Domenech, Josep, Begoña Mellado, Berta Ferrer-Rosell, et al.. (2005). Activation of nuclear factor-κB in human prostate carcinogenesis and association to biochemical relapse. British Journal of Cancer. 93(11). 1285–1294. 101 indexed citations

19.

Codony‐Servat, Jordi, Joan Albanell, Juan Carlos López-Talavera, Joaquı́n Arribas, & José Baselga. (1999). Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells.. PubMed. 59(6). 1196–201. 193 indexed citations

20.

Codony‐Servat, Jordi, Ramón Gimeno, Carmen Gelpí, J. L. Rodríguez-Sánchez, & C. Juárez. (1996). The two isoforms of the 90-kDalton nucleolus organizer region autoantigen (upstream binding factor) bind with different avidity to DNA modified by the antitumor drug cisplatin. Biochemical Pharmacology. 51(9). 1131–1136. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact